KTE-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study From the DESCAR-T Registry and LYSA Group

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [41] IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A REAL-LIFE, RETROSPECTIVE, MULTICENTER TRIAL ON BEHALF OF THE "RTL" (REGIONAL TUSCAN LYMPHOMA NETWORK)
    Cencini, E.
    Mecacci, B.
    Morelli, F.
    Ghio, F.
    Romano, I.
    Birtolo, S.
    Simonetti, F.
    Zoi, V.
    Moretti, S.
    Sant'Antonio, E.
    Cuccaro, A.
    Santini, S.
    Kovalchuk, S.
    Puccini, B.
    Galimberti, S.
    Bocchia, M.
    Fabbri, A.
    HAEMATOLOGICA, 2021, 106 (10) : 142 - 143
  • [42] Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick Lundry
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian
    McSweeney, Peter A.
    Miklos, David Bernard
    Kersten, Marie Jose
    Bouabdallah, Krimo
    Topp, Max S.
    Shen, Rhine
    Kloos, Ioana
    Peng, Weimin
    Fang, Xiang
    Reagan, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
    Wayne, Alan S.
    Michel, Gerard
    Lee, Daniel W.
    Baruchel, Andre
    Chaudhury, Sonali
    Brown, Patrick A.
    Hermiston, Michelle
    Krueger, Joerg
    Shen, Tong
    Tailford, Kristy
    Masouleh, Behzad Kharabi
    BLOOD, 2020, 136
  • [44] Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium
    Wang, Yucai
    Jain, Preetesh
    Locke, Frederick L.
    Munoz, Javier
    Maurer, Matthew J.
    Beitinjaneh, Amer
    Frank, Matthew J.
    Dahiya, Saurabh
    McGuirk, Joseph P.
    Jacobs, Miriam T.
    Goy, Andre H.
    Vose, Julie M.
    Hill, Brian T.
    Oluwole, Olalekan O.
    Deol, Abhinav
    Shah, Bijal D.
    Paludo, Jonas
    Wang, Trent
    Lekakis, Lazaros J.
    Miklos, David B.
    Rapoport, Aaron P.
    Ghobadi, Armin
    Neelapu, Sattva S.
    Lin, Yi
    Wang, Michael
    Jain, Michael D.
    BLOOD, 2021, 138
  • [45] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
    Shah, Bijal D.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Holmes, Houston
    Arellano, Martha L.
    Ghobadi, Armin
    Pagel, John M.
    Lin, Yi
    Cassaday, Ryan D.
    Park, Jae H.
    Abedi, Mehrdad
    Castro, Januario E.
    DeAngelo, Daniel J.
    Malone, Adriana K.
    Mawad, Raya
    Schiller, Gary J.
    Rossi, John M.
    Bot, Adrian
    Shen, Tong
    Goyal, Lovely
    Jain, Rajul K.
    Vezan, Remus
    Wierda, William G.
    BLOOD, 2021, 138 (01) : 11 - 22
  • [46] ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
    Wang, Michael
    Locke, Frederick Lundry
    Munoz, Javier
    Goy, Andre
    Holmes, Houston Eccleston
    Siddiqi, Tanya
    Flinn, Ian
    McSweeney, Peter A.
    Reagan, Patrick Michael
    Hill, Brian Thomas
    Jacobson, Caron A.
    Rizzieri, David A.
    Heffner, Leonard T.
    Jaglowski, Samantha Mary
    Miklos, David Bernard
    Shaughnessy, Paul
    Unabia, Sherry
    Rossi, John M.
    Jiang, Yizhou
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
    Wang, Michael
    Rossi, John M.
    Munoz, Javier
    Goy, Andre H.
    Locke, Frederick L.
    Reagan, Patrick M.
    Jacobson, Caron A.
    Hill, Brian T.
    Holmes, Houston
    Jaglowski, Samantha
    Peng, Weimin
    Zheng, Lianqing
    Fang, Xiang
    Xue, Allen
    Kloos, Ioana
    Bot, Adrian
    BLOOD, 2020, 136
  • [48] ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Kenderian, Saad S.
    Flinn, Ian W.
    Hill, Brian T.
    Maris, Michael
    Ghia, Paolo
    Byrne, Michael
    Bartlett, Nancy L.
    Pagel, John M.
    Zheng, Yan
    Kanska, Justyna
    Zhang, Wangshu
    Masouleh, Behzad Kharabi
    Granados, Enrique
    Ibarz, Javier Pinilla
    BLOOD, 2022, 140 : 7454 - 7456
  • [49] Brexucabtagene Autoleucel for Relapsed/ Refractory Mantle Cell Lymphoma: Real-World Experience From the US Lymphoma CAR T Consortium
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 16 - 18
  • [50] French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
    Ferment, Benoit
    Lambert, Jerome
    Caillot, Denis
    Lafon, Ingrid
    Karlin, Lionel
    Lazareth, Anne
    Touzeau, Cyrille
    Leleu, Xavier
    Moya, Niels
    Harel, Stephanie
    Perrot, Aurore
    Bories, Pierre
    Vincent, Laure
    Lamure, Sylvain
    Mohty, Mohamad
    Malard, Florent
    Manier, Salomon
    Yakoub-Agha, Ibrahim
    Stoppa, Anne-Marie
    Brisou, Gabriel
    Decaux, Olivier
    Houot, Roch
    Le Gouill, Steven
    Facon, Thierry
    Avet-Loiseau, Herve
    Moreau, Philippe
    Arnulf, Bertrand
    BLOOD, 2022, 140 : 4668 - 4670
12345